Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Parenthetical)

v3.5.0.2
Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Parenthetical) - Series C Convertible Preferred Stock [Member]
9 Months Ended
Sep. 30, 2016
USD ($)
Gross proceeds for sale of series C convertible preferred stock $ 1,367,120
Sale of Series C convertible preferred stock, issuance costs 211,835
Sale of Series C convertible preferred stock, cash 150,383
Sale of Series C convertible preferred stock, non-cash 61,452
Issuance of warrants $ 178,414